WG
BBIO icon

Winton Group’s BridgeBio Pharma BBIO Stock Holding History

Winton Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-47,925
Closed -$3.56M – 1184
2026
Q1 		$3.56M Buy
+47,925
New +$3.47M 0.12% 217
2025
Q3 		– Sell
-89,312
Closed -$3.86M – 737
2025
Q2 		$3.86M Buy
+89,312
New +$3.25M 0.2% 139
2024
Q4 		– Sell
-28,091
Closed -$715K – 619
2024
Q3 		$715K Buy
+28,091
New +$737K 0.05% 381
2023
Q2 		– Sell
-14,312
Closed -$237K – 787
2023
Q1 		$237K Buy
+14,312
New +$167K 0.01% 866
2022
Q1 		– Sell
-13,253
Closed -$221K – 959
2021
Q4 		$221K Sell
13,253
-1,767
-12% -$74.8K 0.01% 921
2021
Q3 		$704K Buy
+15,020
New +$805K 0.04% 686

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Winton Group's BBIO Position: Q2 2026 in Review

Winton Group sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 47,925 shares — an estimated $3.56M sold.

Winton Group first reported a position in BBIO in Q3 2021 and held it in 6 quarters. The position peaked at $3.86M in Q2 2025. 472 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Winton Group reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • Winton Group sold 47,925 BridgeBio Pharma shares in Q2 2026, an estimated $3.56M.
  • Winton Group first reported a position in BridgeBio Pharma in Q3 2021 and held it in 6 quarters.
  • Winton Group's BridgeBio Pharma position peaked at $3.86M in Q2 2025.
  • 472 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.